Psoriasis | UCB | PS0007
Pharmaceutical Company/Sponsor:
UCB
Code:
PS0007
Title:
Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled (12-17 Years) Including a Single Open-Label Arm (6-11 Years) Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol (CZP) in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO)
Type:
Interventional
Phase:
3
Condition/Disease:
Psoriasis
Intervention(s)/Treatment(s):
Drug: Certolizumab pegol
Drug: Placebo
Status:
Completed
Link for Additional Information:
